FOUNDATIONONE® LIQUID CDx

PATIENT
Li, Fang-Liang

TUMOR TYPE
Liver cholangiocarcinoma
COUNTRY CODE
TW

REPORT DATE
16 Dec 2021
ORDERED TEST #
ORD-1253329-01

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT
DISEASE Liver cholangiocarcinoma
NAME Li, Fang-Liang
DATE OF BIRTH 10 June 1957
SEX Male
MEDICAL RECORD # 47919197

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN ID FLL 6/10/1957
SPECIMEN TYPE Blood
DATE OF COLLECTION 02 December 2021
SPECIMEN RECEIVED 10 December 2021

Biomarker Findings

Blood Tumor Mutational Burden - 4 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Elevated Tumor Fraction Not Detected

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

IDH1 R132L
KRAS G13D, G12D
BAP1 C91Y
TP53 P177_C182del, P92L

† See About the Test in appendix for details.

Report Highlights

- Targeted therapies with **NCCN categories of evidence** in this tumor type: **Ivosidenib** (p. 9)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 10)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS
Blood Tumor Mutational Burden - 4 Muts/Mb	**No therapies or clinical trials. See Biomarker Findings section**
Microsatellite status - MSI-High Not Detected	**MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).**
Tumor Fraction - Elevated Tumor Fraction Not Detected	**Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. The fact that elevated tumor fraction was not detected in this specimen indicates the possibility of lower levels of ctDNA but does not compromise confidence in any reported alterations. However, in the setting of a negative liquid biopsy result, orthogonal testing of a tissue specimen should be considered if clinically indicated (see Biomarker Findings section).**

GENOMIC FINDINGS		VAF %	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
IDH1 -	R132L	6.0%	Ivosidenib 2A	None
10 Trials see p. 10				
KRAS -	G13D	0.19%	None	None
	G12D	6.5%		
3 Trials see p. 12				

☐ *NCCN category*

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

BAP1 - C91Y ..... p. 7

TP53 - P177_C182del, P92L ..... p. 8

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF1*, *NF2*, *PALB2*, *PMS2*, *POLE*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531



HISTORIC PATIENT FINDINGS		ORD-1253329-01 VAF%
Blood Tumor Mutational Burden		4 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		Elevated Tumor Fraction Not Detected
IDH1	R132L	6.0%
KRAS	G12D	6.5%
	G13D	0.19%
BAP1	C91Y	6.6%
TP53	P177_C182del	0.09%
	P92L	49.7%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx, FoundationOne®Liquid, FoundationOne®, or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

VAF% = variant allele frequency percentage
Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Blood Tumor Mutational Burden

RESULT
4 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-2] and anti-PD-1[3] therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb[1]. In HNSCC, a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[4].

FREQUENCY & PROGNOSIS

Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)[5-7]. Published data investigating the prognostic implications of bTMB levels in biliary tract cancer are limited (PubMed, Jul 2021). Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study[8], TMB-high (≥10 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB-high tumors experienced numerically longer OS compared with patients with TMB-low tumors (11.5 vs. 8.4 months, adjusted HR=0.65)[9].

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[10-11] and cigarette smoke in lung cancer[12-13], treatment with temozolomide-based chemotherapy in glioma[14-15], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[16-20], and microsatellite instability (MSI)[16,19-20]. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-3]. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT
Elevated Tumor Fraction Not Detected

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with elevated tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[21-26].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[27]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[28], Ewing sarcoma and osteosarcoma[29], prostate cancer[24], breast cancer[30], leiomyosarcoma[31], esophageal cancer[32], colorectal cancer[33], and gastrointestinal cancer[34].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[35], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[36-37].

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
IDH1

ALTERATION
R132L

TRANSCRIPT ID
NM_005896

CODING SEQUENCE EFFECT
395G>T

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

IDH1 mutations that lead to production of 2-HG, most commonly R132 alterations, may predict sensitivity to IDH1-mutation-specific inhibitors such as ivosidenib[38]. A Phase 1b/2 study of the IDH1 inhibitor olutasidenib for patients with IDH1-mutated glioma reported a DCR of 50% (n=24) with 1 PR[39]. A Phase 1 study of the pan-IDH1/IDH2 inhibitor vorasidenib for patients with IDH1- or IDH2-mutated glioma reported an ORR of 18.2% (4/22; RANO criteria) and median PFS of 31.4 months for non-enhancing cases and median PFS of 7.5 months for the overall glioma population (n=52)[40]. Preclinical studies suggested that IDH1 neomorphic mutations may also confer sensitivity to PARP inhibitors[41-44].

FREQUENCY & PROGNOSIS

IDH1 or IDH2 mutation has been reported in 10-23% of cholangiocarcinoma cases and has been found to be more prevalent in intrahepatic (22-28%) than extrahepatic (0-7%) cholangiocarcinomas[45-50]. In patients with intrahepatic cholangiocarcinoma, IDH1/2 mutations are associated with longer OS and increased time to tumor recurrence[50]. A preclinical study observed that mutant IDH can block hepatocyte differentiation and cooperate with oncogenic KRAS to drive cholangiocarcinoma development[51].

FINDING SUMMARY

The isocitrate dehydrogenases IDH1 and IDH2 encode highly homologous enzymes that are involved in the citric acid (TCA) cycle and other metabolic processes, playing roles in normal cellular metabolism and in protection against oxidative stress and apoptosis[52]. R132 is located within the active site of IDH1 and is a hotspot for mutations in cancer[52-56]. Substitutions at IDH1 R132 alter the enzymatic activity of IDH1, resulting in the production of the oncometabolite, D-2-hydroxyglutarate (2-HG)[54-58], which promotes tumorigenesis[54,59-62].

GENE
KRAS

ALTERATION
G13D, G12D

TRANSCRIPT ID
NM_004985, NM_004985

CODING SEQUENCE EFFECT
38G>A, 35G>A

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

In a Phase 1 study evaluating the MEK-pan-RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non-small cell lung cancer (NCSLC), 1 with low-grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma[63]. Another Phase 1 study of CH5126766 combined with the FAK inhibitor defactinib reported 4 PRs in KRAS-mutated LGSOC[64]. Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors[65-66]. A Phase 1 study of RMC-4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations[67]. Interim results from a Phase 1/2 study of RMC-4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS-mutated colorectal cancer[68]. Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib[69-74]. Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors[75-76]. Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations[77-78] . However, Phase 1 and Phase 2 trials of MEK inhibitor monotherapies reported no objective responses (4/4 SD) for patients with biliary tract cancer harboring KRAS mutations[79-80]. Although a Phase 1/2 study of binimetinib in combination with gemcitabine and cisplatin observed a 33% ORR (1 PR, n=3) for patients with KRAS-mutated advanced biliary tract cancer, this was comparable with the 36% ORR (3 CRs, 9 PRs, n=33) of the overall study population[81]. One study reported that patients with mutations in the RAS-MAPK pathway may be sensitive to binimetinib and capecitabine; patients with KRAS-, NRAS-, or MEK-mutated gemcitabine-pretreated biliary tract cancer experienced improved mPFS (5.4 vs. 2.6 months, p=0.031), mOS (10.8 vs. 5.3 months, p=0.011), and ORR (40% vs. 12.5%) as compared with patients lacking these mutations[82].

FREQUENCY & PROGNOSIS

KRAS mutations have been observed with an incidence of 13-50% in cholangiocarcinoma[45,49,83-87]. One study observed a higher frequency of KRAS mutations in intrahepatic cholangiocarcinomas with bile duct histology (23/98) versus tumors with cholangiolar histology (1/76)[85]. While some studies have reported no association between KRAS mutation and prognosis in cholangiocarcinoma[85,88], other studies have reported an association of KRAS mutation with poorer survival in patients with gallbladder or extrahepatic biliary tract cancers[89-90].

FINDING SUMMARY

KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation[70,91]. KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, R68S, and K117N have been characterized as activating and oncogenic[70,92-114].

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
BAP1

ALTERATION
C91Y

TRANSCRIPT ID
NM_004656

CODING SEQUENCE EFFECT
272G>A

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Clinical[115] and preclinical[116] evidence in the context of mesothelioma suggests that tumors with BAP1 inactivation may be sensitive to EZH2 inhibitors such as tazemetostat. Preclinical studies suggest that BAP1 is involved in the DNA damage response[117-120], and BAP1 inactivation might be associated with sensitivity to PARP inhibitors[118-119]. One preclinical study suggests that HDAC inhibitors may be beneficial in BAP1-mutated uveal melanoma; however, it is unclear if these inhibitors are effective in other BAP1-mutated cancers[121].

FREQUENCY & PROGNOSIS

In cholangiocarcinoma, BAP1 mutation has been reported in 7-27% of cases[122-124] with one study reporting higher frequency in cases unrelated to to liver fluke (O. viverrini) infection (10% versus 3%)[122]. BAP1 loss has been reported in 0-2% of cholangiocarcinomas[125-126]. Loss of BAP1 protein expression was reported in 19.4% of patients with intrahepatic cholangiocarcinoma[127]. In a study of intrahepatic cholangiocarcinoma, BAP1 protein loss significantly associated with improved overall and recurrence-fee survival[127]. In patients with gallbladder carcinoma, a significant association between low BAP1 expression and reduced median overall survival was reported[128].

FINDING SUMMARY

BAP1 (BRCA1 associated protein-1) encodes a ubiquitin hydrolase, a protein involved in regulating the availability of target proteins for the ubiquitin-proteasome protein degradation pathway; BAP1 is located on chromosome 3p21.3, in a region of frequent loss of heterozygosity (LOH) in breast and lung cancer, and has been postulated to be a tumor suppressor[129-130]. Alterations such as seen here may disrupt BAP1 function or expression[122,130-138].

POTENTIAL GERMLINE IMPLICATIONS

BAP1 germline inactivating alterations, including mutations and deletions, are associated with BAP1 tumor predisposition syndrome (BAP1-TPDS), an autosomal-dominant syndrome characterized by early onset of benign melanocytic skin tumors[132,139-140]. An estimated 2% of patients with BAP1-inactivated melanocytic tumors display germline BAP1 mutations[141]. Later in life, patients have an increased risk of cancers such as uveal melanoma, mesothelioma, clear cell renal cell carcinoma, basal cell carcinoma, and meningioma[131-135,142]. In small studies, the prevalence of pathogenic germline BAP1 mutation has been reported as 22% in familial uveal melanoma and 4.4% in mesothelioma[143-144]. In the appropriate clinical context, germline testing of BAP1 is recommended.

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
TP53

ALTERATION
P177_C182del, P92L

TRANSCRIPT ID
NM_000546, NM_000546

CODING SEQUENCE EFFECT
529_546delCCCCACCATGAGCGCTGC, 275C>T

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[145-148], or p53 gene therapy and immunotherapeutics such as SGT-53[149-153] and ALT-801[154]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) for patients with TP53 mutations versus 12.1% (4/33) for patients who were TP53 wild-type[155]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[156]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[157]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[158]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel[159]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations[160]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[153]. Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53-mutated, but not TP53-wild-type, breast cancer xenotransplant mouse model[161]. Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR-246[162-164]. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, APR-246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[165]. ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies[166-167]; however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies[168-169]. Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition.

FREQUENCY & PROGNOSIS

Inactivation of p53, through mutation, deletion, or loss of heterozygosity (LOH), has been observed in 25-63% of gallbladder carcinomas and 10-61% of cholangiocarcinomas[8,48-49,122-123,170-174]. TP53 mutations occur more frequently in tumors caused by liver fluke (O. viverrini) infection (40%) than in cholangiocarcinoma cases not related to infection (9%)[122]. Aberrant TP53 expression, which is indicative of TP53 dysregulation, has been observed in 20–62% of gallbladder carcinomas and 25% (5/20) of cholangiocarcinomas[175-177]. Data regarding the prognostic significance of TP53 mutation in cholangiocarcinoma are conflicting[178-186]. Overexpression of p53 protein has been associated with reduced patient survival in poorly differentiated gallbladder adenocarcinomas and biliary tract cancers[187-188]; however, another study did not find such a correlation[180].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[189]. Alterations such as seen here may disrupt TP53 function or expression[190-194]. Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance.

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[195-197], including sarcomas[198-199]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[200] to 1:20,000[199]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[201]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[202-207]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[202-203]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[208]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[206,209-210]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Ivosidenib

Assay findings association

IDH1
R132L

AREAS OF THERAPEUTIC USE

Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved to treat patients with a susceptible IDH1 mutation in relapsed or refractory acute myeloid leukemia (AML) or previously treated locally advanced or metastatic cholangiocarcinoma. It is also approved as a first-line treatment for patients with AML and a susceptible IDH1 mutation who are not eligible for intensive induction chemotherapy or who are ≥75 years old. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of extensive clinical evidence in AML[211] and cholangiocarcinoma[212-213] and limited clinical data in myelodysplastic syndrome (MDS)[211] and glioma[38,214] , IDH1 R132 mutation may confer sensitivity to ivosidenib.

SUPPORTING DATA

In the Phase 3 ClarIDHy trial for patients with previously treated IDH1 R132-mutated cholangiocarcinoma, ivosidenib significantly increased PFS (2.7 vs. 1.4 months, HR=0.37, p <0.001) as well as PFS rates compared with placebo (6-month: 32% vs. 0%, 12-month: 22% vs. 0%) and reported numerically increased OS (10.3 vs. 7.5 months, HR=0.79, p=0.09), which reached statistical significance once adjusted for crossover (10.3 vs. 5.1 months, HR=0.49, p <0.0001)[213,215] . A Phase 1 study reported an ORR of 5.6% (4/72, all PRs), SD rate of 56% (40/72), median PFS of 3.8 months, and median OS of 13.8 months for patients with IDH1-mutated cholangiocarcinoma treated with ivosidenib[212].

NOTE Genomic alterations detected may be associated with activity of certain US FDA or other specific country approved therapies; however, the therapies listed in this report may have varied evidence in the patient's tumor type. The listed therapies are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. The therapies listed in this report may not be complete and/or exhaustive. Furthermore, the listed therapies are limited to US FDA approved pharmaceutical drug products that are linked to a specific genomic alteration. There may also be US FDA approved pharmaceutical drug products that are not linked to a genomic alteration. Further there may also exist pharmaceutical drug products that are not approved by the US FDA or other national authorities. There may also be other treatment modalities available than pharmaceutical drug products.

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE

IDH1

ALTERATION

R132L

RATIONALE

IDH1 mutations may predict sensitivity to IDH1 inhibitors. On the basis of preclinical data, IDH1 mutations may also confer sensitivity to PARP inhibitors in solid tumors.

NCT02264678

PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California

NCT04298021

PHASE 2

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

TARGETS
PD-L1, ATR, PARP

LOCATIONS: Seoul (Korea, Republic of)

NCT03772561

PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT04497116

PHASE 1/2

Study of RP-3500 in Advanced Solid Tumors

TARGETS
ATR, PARP

LOCATIONS: Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT03907969

PHASE 1/2

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers

TARGETS
PARP, DNA-PK

LOCATIONS: Newcastle upon Tyne (United Kingdom), London (United Kingdom), Connecticut, Texas

NCT03878095

PHASE 2

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

TARGETS
ATR, PARP

LOCATIONS: Utah, Wisconsin, Michigan, Ohio, Connecticut, Maryland, Texas, Florida

NCT03830918

PHASE 1/2

Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

TARGETS
PARP

LOCATIONS: California

NCT03212274

PHASE 2

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

TARGETS
PARP

LOCATIONS: California, Wisconsin, Missouri, Kansas

NCT03221400

PHASE 1/2

PEN-866 in Patients With Advanced Solid Malignancies

TARGETS
PARP, HSP90

LOCATIONS: Nevada, Colorado, Michigan, Oklahoma, Arkansas, Tennessee, Pennsylvania, Maryland, Virginia

GENE
KRAS

ALTERATION
G13D, G12D

RATIONALE
KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK-pan-RAF dual inhibitors. Limited clinical evidence suggests that MEK inhibitors in combination with chemotherapy may be an effective treatment for patients with KRAS-, NRAS-, or MEK-mutated biliary tract cancer.

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT03905148

PHASE 1/2

Study of the Safety and Pharmacokinetics of BGB-283 and PD-0325901 in Patients With Advanced or Refractory Solid Tumors

TARGETS
RAFs, EGFR, MEK

LOCATIONS: Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas

NCT04111458

PHASE 1

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

TARGETS
KRAS, SOS1, MEK

LOCATIONS: Frankfurt am Main (Germany), Köln (Germany), Utrecht (Netherlands), Rotterdam (Netherlands), Massachusetts, Tennessee, Texas, North Carolina

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

APC
A239P

ATR
T2556S

CXCR4
P31H

DNMT3A
R635G

MYCL1
L327Q

PTCH1
S1280L

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*C11orf30* (EMSY)	*C17orf39* (GID4)	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*
CCND1	*CCND2*	*CCND3*	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*
CD274 **(PD-L1)**	*CDC73*	***CDH1***	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*
CDKN2A	*CDKN2B*	*CDKN2C*	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***
CSF1R	*CSF3R*	*CTCF*	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*
DAXX	*DDR1*	***DDR2*** **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15**, 24-27**	*EP300*
EPHA3	*EPHB1*	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***
ESR1 **Exons 4-8**	*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FAM46C*	*FANCA*
FANCC	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*
FGF23	*FGF3*	*FGF4*	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*
FLCN	*FLT1*	***FLT3*** **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*
GNA11 **Exons 4, 5**	*GNA13*	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3F3A*	*HDAC1*	*HGF*
HNF1A	***HRAS*** **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*
INPP4B	*IRF2*	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*
KDM5C	*KDM6A*	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

KRAS	*LTK*	*LYN*	*MAF*	***MAP2K1*** **(MEK1) Exons 2, 3**	***MAP2K2*** **(MEK2) Exons 2-4, 6, 7**	*MAP2K4*	*MAP3K1*	*MAP3K13*
MAPK1	*MCL1*	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***
MITF	*MKNK1*	*MLH1*	***MPL*** **Exon 10**	*MRE11A*	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*
MTAP	***MTOR*** **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*
NF1	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**
NRAS **Exons 2, 3**	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*	***PALB2***
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**
PDGFRB **Exons 12-21, 23**	*PDK1*	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*	***RET*** Introns 7, 8, **Exons 11, 13-16, Introns 9-11**
RICTOR	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*
SMO	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*
STAT3	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TERC** ncRNA	***TERT**** **Promoter**	*TET2*
TGFBR2	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*	*TSC2*	*TYRO3*
U2AF1	***VEGFA***	*VHL*	*WHSC1*	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status

Blood Tumor Mutational Burden (bTMB)

Tumor Fraction

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from the observed level of aneuploidy in the sample. Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected and is significantly distinct from that typically found in non-tumor samples.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.2.0

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
4. Li et al., 2020; ASCO Abstract 6511
5. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
6. Gao J, et al. Sci Signal (2013) pmid: 23550210
7. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
8. Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846
9. Shao C, et al. JAMA Netw Open (2020) pmid: 33119110
10. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
11. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
12. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
13. Rizvi NA, et al. Science (2015) pmid: 25765070
14. Johnson BE, et al. Science (2014) pmid: 24336570
15. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
16. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
17. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
18. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
19. Nature (2012) pmid: 22810696
20. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
21. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
22. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
23. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
24. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
25. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
26. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
27. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
28. Lapin M, et al. J Transl Med (2018) pmid: 30400802
29. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
30. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
31. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
32. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
33. Fan G, et al. PLoS ONE (2017) pmid: 28187169
34. Vu et al., 2020; DOI: 10.1200/PO.19.00204
35. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
36. Zhang EW, et al. Cancer (2020) pmid: 32757294
37. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
38. Fan B, et al. Invest New Drugs (2019) pmid: 31028664
39. De La Fuente et al., 2020; ASCO Abstract 2505
40. Mellinghoff et al., 2020; ASCO Abstract 2504
41. Philip B, et al. Cell Rep (2018) pmid: 29719265
42. Molenaar RJ, et al. Clin. Cancer Res. (2018) pmid: 29339439
43. Lu Y, et al. Cancer Res. (2017) pmid: 28202508
44. Sulkowski PL, et al. Sci Transl Med (2017) pmid: 28148839
45. Voss JS, et al. Hum. Pathol. (2013) pmid: 23391413
46. Sia D, et al. Oncogene (2013) pmid: 23318457
47. Kipp BR, et al. Hum. Pathol. (2012) pmid: 22503487
48. Ross JS, et al. Oncologist (2014) pmid: 24563076
49. Borger DR, et al. Oncologist (2012) pmid: 22180306
50. Wang P, et al. Oncogene (2013) pmid: 22824796
51. Saha SK, et al. Nature (2014) pmid: 25043045
52. Reitman ZJ, et al. J. Natl. Cancer Inst. (2010) pmid: 20513808
53. Jin G, et al. PLoS ONE (2011) pmid: 21326614
54. Gross S, et al. J. Exp. Med. (2010) pmid: 20142433
55. Ward PS, et al. Cancer Cell (2010) pmid: 20171147
56. Leonardi R, et al. J. Biol. Chem. (2012) pmid: 22442146
57. Dang L, et al. Nature (2009) pmid: 19935646
58. Ward PS, et al. Oncogene (2012) pmid: 21996744
59. Figueroa ME, et al. Cancer Cell (2010) pmid: 21130701
60. Xu W, et al. Cancer Cell (2011) pmid: 21251613
61. Turcan S, et al. Nature (2012) pmid: 22343889
62. Duncan CG, et al. Genome Res. (2012) pmid: 22899282
63. Norton ML, et al. Leg Med (1986) pmid: 3312887
64. Shinde et al., 2020; AACR Abstract CT143
65. Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384
66. Mainardi S, et al. Nat Med (2018) pmid: 29808006
67. Koczywas et al., 2021; AACR Abstract LB001
68. Bendell et al., 2020; EORTC-NCI-AACR Abstract 5
69. Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174
70. Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244
71. Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318
72. Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367
73. Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089
74. Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556
75. Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722
76. Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843
77. Hofmann et al., 2021; AACR Abstract CT210
78. Gort et al., 2020; ASCO Abstract TPS3651
79. Finn RS, et al. Invest New Drugs (2018) pmid: 29785570
80. Bekaii-Saab T, et al. J. Clin. Oncol. (2011) pmid: 21519026
81. Lowery MA, et al. Clin. Cancer Res. (2019) pmid: 30563938
82. Kim et al., 2018; ASCO Abstract 4079
83. Hsu M, et al. Cancer (2013) pmid: 23335286
84. Chang YT, et al. J. Gastroenterol. Hepatol. (2014) pmid: 24372748
85. Liau JY, et al. Mod. Pathol. (2014) pmid: 24406866
86. O'Dell MR, et al. Cancer Res. (2012) pmid: 22266220
87. Andersen JB, et al. Gastroenterology (2012) pmid: 22178589
88. Borbath I, et al. Ann. Oncol. (2013) pmid: 23975665
89. Javle M, et al. Hum. Pathol. (2014) pmid: 24508317
90. Malats N, et al. J. Clin. Oncol. (1995) pmid: 7602358
91. Kahn S, et al. Anticancer Res. () pmid: 3310850
92. Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185
93. Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068
94. Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776
95. Sci. STKE (2004) pmid: 15367757
96. Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076
97. Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178
98. Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621
99. Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890
100. Kim E, et al. Cancer Discov (2016) pmid: 27147599
101. Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576
102. Naguib A, et al. J Mol Signal (2011) pmid: 21371307
103. Prior IA, et al. Cancer Res. (2012) pmid: 22589270
104. Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661
105. Scheffzek K, et al. Science (1997) pmid: 9219684
106. Scholl C, et al. Cell (2009) pmid: 19490892
107. Smith G, et al. Br. J. Cancer (2010) pmid: 20147967
108. Tyner JW, et al. Blood (2009) pmid: 19075190
109. Valencia A, et al. Biochemistry (1991) pmid: 2029511
110. White Y, et al. Nat Commun (2016) pmid: 26854029
111. Wiest JS, et al. Oncogene (1994) pmid: 8058307
112. Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513
113. Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870
114. Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033
115. Zauderer et al., 2018; ASCO Abstract 8515
116. LaFave LM, et al. Nat. Med. (2015) pmid: 26437366
117. Yu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2014) pmid: 24347639
118. Ismail IH, et al. Cancer Res. (2014) pmid: 24894717
119. Peña-Llopis S, et al. Nat. Genet. (2012) pmid: 22683710
120. Nishi R, et al. Nat. Cell Biol. (2014) pmid: 25194926
121. Landreville S, et al. Clin. Cancer Res. (2012) pmid: 22038994
122. Chan-On W, et al. Nat. Genet. (2013) pmid: 24185513
123. Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509
124. Simbolo M, et al. Oncotarget (2014) pmid: 24867389
125. Sanchez-Vega F, et al. Cell (2018) pmid: 29625050
126. Lowery MA, et al. Clin. Cancer Res. (2018) pmid: 29848569
127. Misumi K, et al. Histopathology (2017) pmid: 27864835
128. Hirosawa T, et al. PLoS ONE (2018) pmid: 30395583
129. Jensen DE, et al. Oncogene (1998) pmid: 9528852
130. Ventii KH, et al. Cancer Res. (2008) pmid: 18757409
131. Abdel-Rahman MH, et al. J. Med. Genet. (2011) pmid: 21941004
132. Testa JR, et al. Nat. Genet. (2011) pmid: 21874000
133. Wiesner T, et al. Nat. Genet. (2011) pmid: 21874003
134. Farley MN, et al. Mol. Cancer Res. (2013) pmid: 23709298
135. Aoude LG, et al. PLoS ONE (2013) pmid: 23977234
136. Peng H, et al. Cancer Res (2018) pmid: 29284740
137. Nishikawa H, et al. Cancer Res (2009) pmid: 19117993
138. Zhang Y, et al. Nat Cell Biol (2018) pmid: 30202049
139. Walpole S, et al. J Natl Cancer Inst (2018) pmid: 30517737
140. Boru G, et al. Genes Chromosomes Cancer (2019) pmid: 30883995
141. Garfield EM, et al. J Am Acad Dermatol (2018) pmid: 29753057
142. Shankar GM, et al. Neuro Oncol (2017) pmid: 28170043
143. Rai K, et al. Genes Chromosomes Cancer (2017) pmid: 27718540
144. Zauderer MG, et al. J Thorac Oncol (2019) pmid: 31323388
145. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
146. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
147. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
148. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
149. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
150. Xu L, et al. Mol. Med. (2001) pmid: 11713371
151. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
152. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
153. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
154. Hajdenberg et al., 2012; ASCO Abstract e15010
155. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
156. Moore et al., 2019; ASCO Abstract 5513
157. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
158. Oza et al., 2015; ASCO Abstract 5506

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

159. Lee J, et al. Cancer Discov (2019) pmid: 31315834
160. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
161. Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188
162. Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953
163. Mohell N, et al. Cell Death Dis (2015) pmid: 26086967
164. Fransson Å, et al. J Ovarian Res (2016) pmid: 27179933
165. Gourley et al., 2016; ASCO Abstract 5571
166. Kwok M, et al. Blood (2016) pmid: 26563132
167. Boudny M, et al. Haematologica (2019) pmid: 30975914
168. Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704
169. Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241
170. Li M, et al. Nat. Genet. (2014) pmid: 24997986
171. Suto T, et al. J Surg Oncol (2000) pmid: 10738270
172. Ong CK, et al. Nat. Genet. (2012) pmid: 22561520
173. Javle M, et al. Cancer (2016) pmid: 27622582
174. Nault JC, et al. Semin. Liver Dis. (2011) pmid: 21538283
175. Won HS, et al. BMC Cancer (2010) pmid: 20955617
176. Chaube A, et al. BMC Cancer (2006) pmid: 16686942
177. Chuang SC, et al. World J Surg (2004) pmid: 15573254
178. Ruzzenente A, et al. Ann. Surg. Oncol. (2016) pmid: 26717940
179. Xiaofang L, et al. World J Surg Oncol (2012) pmid: 22230750
180. Ajiki T, et al. Hepatogastroenterology () pmid: 8799388
181. J Surg Oncol (2006) pmid: 16724348
182. Guo R, et al. Hum. Pathol. (2014) pmid: 24746206
183. Boerner T, et al. Hepatology (2021) pmid: 33765338
184. Conci S, et al. Updates Surg (2020) pmid: 32020551
185. Simbolo M, et al. Sci Rep (2018) pmid: 29740198
186. Churi CR, et al. PLoS ONE (2014) pmid: 25536104
187. Lee CS, et al. Pathology (1995) pmid: 7567135
188. Ahrendt SA, et al. J Hepatobiliary Pancreat Surg (2000) pmid: 11180865
189. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
190. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
191. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
192. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
193. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
194. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
195. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
196. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
197. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
198. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
199. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
200. Lalloo F, et al. Lancet (2003) pmid: 12672316
201. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713
202. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
203. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
204. Xie M, et al. Nat. Med. (2014) pmid: 25326804
205. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
206. Severson EA, et al. Blood (2018) pmid: 29678827
207. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
208. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
209. Chabon JJ, et al. Nature (2020) pmid: 32269342
210. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
211. DiNardo CD, et al. N. Engl. J. Med. (2018) pmid: 29860938
212. Lowery MA, et al. Lancet Gastroenterol Hepatol (2019) pmid: 31300360
213. Abou-Alfa GK, et al. Lancet Oncol. (2020) pmid: 32416072
214. Mellinghoff IK, et al. J. Clin. Oncol. (2020) pmid: 32530764
215. Zhu AX, et al. JAMA Oncol (2021) pmid: 34554208

Electronically signed by Giles Maule, M.D., Ph.D | 16 December 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531